Quadrature Capital’s Orchestra BioMed OBIO Stock Holding History

Quadrature Capital’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,577	Closed	-$38.5K	–	1549
2025 Q3	$38.5K	Buy	+15,577	New	+$43K	﹤0.01%	968

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Quadrature Capital's OBIO Position: Q4 2025 in Review

Quadrature Capital sold out of Orchestra BioMed (OBIO) in Q4 2025, closing a stake of 15,577 shares — an estimated $38.5K sold.

Quadrature Capital first reported a position in OBIO in Q3 2025 and held it in 1 quarter. The position peaked at $38.5K in Q3 2025. 63 funds tracked by Wall St. Rank hold OBIO as of Q4 2025.

Quadrature Capital reported no remaining Orchestra BioMed position as of Q4 2025 after selling out during the quarter.
Quadrature Capital sold 15,577 Orchestra BioMed shares in Q4 2025, an estimated $38.5K.
Quadrature Capital first reported a position in Orchestra BioMed in Q3 2025 and held it in 1 quarter.
Quadrature Capital's Orchestra BioMed position peaked at $38.5K in Q3 2025.
63 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.